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Background. Exogenous bilirubin may reduce experimental ischemia-reperfusion injury (IRI) due to its antioxidant properties. We
studied if early graft exposure to high bilirubin levels in the recipient affects the early IRI and outcomes after liver transplantation
(LTx).Methods. In 427 LTx patients, the AUROC curve based on bilirubin and AST at day 1 identified a cutoff of 2.04mg/dL for the
recipient pretransplant bilirubin. Recipients were grouped as having low (group L, 𝑛 = 152) or high (group H, 𝑛 = 275) bilirubin.
Both groups had similar donor-related variables (age, preservation time, donor BMI > 28, and donor risk index (DRI)). Results.
Alanine (ALT) and aspartate (AST) aminotransferase levels were higher in group L at day 1; ALT levels remained higher at day
2 in group L. LTx from high risk donors (DRI > 2) revealed a trend towards lower transaminases during the first two days after
transplantation in group H. One month and 1-year patient survival were similar in groups L and H. High preoperative bilirubin did
not affect the risk for early graft dysfunction (EGD), death, or graft loss during the first year after transplantation nor the incidence
of acute rejection. LTx using donors with DRI > 2 resulted in similar rates of EGD in both groups. Conclusion. Increased bilirubin
appears to reduce the early IRI after LTx yet this improvement was insufficient to improve the clinical outcome.
1. Introduction
Ischemia-reperfusion injury (IRI) of the liver graft reemerges
as a major issue as the pressure of ever increasing waiting
lists requires the use of extended criteria donor livers with
steatosis, older, and non-heart-beating donors. These grafts
are more susceptible to IRI with up to 10% of the procured
livers not being transplanted due to the risk of primary
graft nonfunction or dysfunction and ischemic type cholan-
giopathy [1]. Several protective strategies aimed at inducing
biological protective mechanisms in the graft or recipient
before the injurious chain of events in the graft occurs
(i.e., ischemic or pharmacologic preconditioning) have been
explored both in clinical and in experimental settings [2–
5]. Although promising, many of these approaches rely on
complex protocols or toxic chemicals or are technically
demanding and expensive (machine perfusion). This often
renders them unpractical and limits their clinical applicabil-
ity.
Bilirubin is a byproduct of heme catabolism occurring
through the heme oxygenase-1 pathway. Bilirubin has been
shown to have potent antioxidant properties [6, 7] and exoge-
nous administration of bilirubin in several models of isolated
organ perfusion has been shown to have a protective effect
against IRI when administered before or during the ischemic
event [8, 9]. Experimental evidence indicates that even a brief
contact with bilirubin is sufficient to confer protection against
IRI [8]. Furthermore, a clinical report suggests a protective
effect of increased endogenous bilirubin against develop-
ment of late graft failure after kidney transplantation [10].
Although the protective mechanisms were unidentified, the
protective effect could be due to the reduction of the oxidative
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stress associated with IRI resulting in reduced reperfusion
injury.
Hyperbilirubinemia is regarded as a negative prognostic
factor in chronic liver disease and is a component of the
Model for End-stage Liver Disease (MELD) reference system,
widely used for allocation of organs for liver transplantation
[11, 12]. However, hyperbilirubinemia may be of benefit in
the very early period after transplantation by mitigating
the oxidative stress upon reperfusion. Therefore, the aim
of this study was to investigate if early graft exposure to
high bilirubin levels in the recipient would have any impact
on the early reperfusion injury and outcomes after liver
transplantation.
2. Patients and Methods
2.1. Study Population. We studied retrospectively all adult
patients who underwent transplantation with a liver from a
brain-dead donor, liver as a single, ABO-compatible, whole
organ at the Transplant Institute at Sahlgrenska University
Hospital between January 2003 and December 2010. We
excluded from the analysis pediatric patients, patients under-
going simultaneous transplantation of other organs, living
donor liver transplants, split liver transplants, portocaval
hemitransposition, or early technical failures/intraoperative
deaths.
2.2. Donor Information. Information on the organ donors
was obtained from the organ report form and Scandiatrans-
plant, the common transplant registry of Sweden, Norway,
Finland, Denmark, and Iceland. Donor data included infor-
mation on donor gender, weight, length, cause of death,
preservation solution, and cold ischemia time (CIT). The
donor risk index (DRI) was computed according to an
acknowledged equation, using a calculator available online
[13, 14]. Concerning the “organ location” parameter in the
formula, the organs procured in Gothenburg and in hospitals
within 60 km were considered as “local,” organs procured
at other donor hospitals from our procurement area (West-
ern, Southern, and Northern Sweden) were considered as
“regional,” and organs shared from other centers within the
Scandiatransplant cooperation were inputted as “national.”
2.3. Liver Transplantation. We retrospectively reviewed pa-
tient files and retrieved information on patient demograph-
ics, underlying disease, MELD, and surgical technique. We
also recorded the length of stay on the intensive care unit and
rejection during the first month after transplantation as well
as one-month and one-year graft and patient survival. The
MELD score refers to the MELD based on laboratory values
obtained shortly prior to transplantation.
The patients were divided into two groups according
to their pretransplant bilirubin levels following a post hoc
analysis using a receiver operating characteristic- (ROC-)
curve. Reperfusion injury was estimated according to the
level of aspartate aminotransferase (AST) and alanine amino-
transferase (ALT) on posttransplantation days 1, 2, and 7.
Early graft dysfunction (EGD) was defined according to
Olthoff et al. with standard criteria as maximum alanine
transferase (ALT) or aspartate transferase (AST) levels >
2000U/L during the first week, international normalized
ratio (INR) ≥ 1.7, or bilirubin > 200micromol/L at the end
of the first postoperative week [15].
Immunosuppression consisted in tacrolimus, mycophe-
nolate mofetil, and steroids until January 2010 and a steroid-
free protocol thereafter.
2.4. Statistical Analysis. Results are presented as mean ±
standard deviation (unless otherwise specified). A receiver
operating characteristic (ROC) curve was constructed by
plotting the sensitivity versus 1 − specificity using the preop-
erative bilirubin and ALT at day 1 to calculate the area under
the ROC curve and to identify a cutoff value of bilirubin.
Following the Kolmogorov-Smirnov test for normality
distribution, differences between groups were assessed with
Student’s 𝑡-test for normally distributed variables or the non-
parametric 𝑈 test (Mann-Whitney) was used for nonnormal
distributed variables. Categorical variables (cause of death,
gender, acute rejection, and retransplantation rate) were
assessed using Fisher’s exact test. Differences were considered
statistically significant when the 𝑝 value was <0.05. The
statistical software used was GraphPad Prism for Windows
Version 5.00 (GraphPad Software, Inc., SanDiego, CA, USA).
3. Results
Five hundred eighty-six liver transplants were performed at
the Sahlgrenska University Hospital in Gothenburg between
January 1st 2003 and December 31st, 2010. One hundred fifty-
nine liver transplants were excluded based on the exclusion
criteria. A post hoc analysis of the remaining 427 patients
using the ROC curve identified a recipient pretransplant
bilirubin concentration of 2.04mg/dL (35micromol/L) as the
cutoff value. Accordingly, the patients (and corresponding
donors) were grouped in a low bilirubin group, group L
(bilirubin < 2.04mg/dL, 𝑛 = 152), and a high bilirubin group,
group H (bilirubin ≥ 2.04mg/dL, 𝑛 = 275).
Donor and graft characteristics did not differ significantly
between groups in terms of age, cold ischemia time, donor
BMI > 28, DRI, or preservation solution.
There was no significant difference between the recipients
in the two groups before transplant except for MELD score
and pretransplant diagnosis. Donor- and recipient-related
variables are summarized in Table 1.
3.1. Posttransplant Transaminase Levels in the First Week as a
Surrogate Marker of Ischemia-Reperfusion Injury. Patients in
group L have had significantly higher ALT and AST at day
1 than patients in group H. ALT levels remained higher at
day 2 in group L while AST showed only a trend towards
higher values (𝑝 = 0.08). One week after transplantation
plasma transaminases reached similar values in the two
groups (Figure 1).
The subgroup analysis of the liver transplants from
donors with DRI > 2 revealed a trend towards lower trans-
aminases during the first two days after transplantation
in recipients with high preoperative bilirubin. One-month
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Table 1: Donor and recipient characteristics.
Group low (𝑛 = 152) Group high (𝑛 = 275) Significance
Donor
Age (SD) 52.3 ± 15 51.5 ± 16 n.s.
Gender (M/F, %) 55.3/44.7 51.1/48.9 n.s.
BMI > 28 (%) 15.2 12 n.s.
Preservation solution
(UW/Custodiol/other, %) 48/52/0 60/48.4/0.6
DRI (mean, SD) 1.67 ± 0.37 1.7 ± 0.39 n.s.
Cold ischemia time (min, mean ± SD) 504 ± 185 519 ± 157 n.s.
Cause of death
Trauma (%) 13.16 10.55
Anoxia (%) 13.16 8.73
Cerebrovascular accident (%) 65.79 60
Other (%) 7.89 20.73
Recipient
Age 53.5 ± 10 50.7 ± 12.4 n.s.
MELD (mean) 9 20.5 0.001
Diagnosis
Hepatocellular cancer, other tumors (%) 29.6 7.2 0.001
Postviral cirrhosis (%) 37.5 23.6 0.01
Sclerosing cholangitis (%) 19.1 21.8 0.05
Primary biliary cirrhosis (%) 2 10 0.01
Laennec cirrhosis (%) 15.8 17 n.s.
Cryptogenic cirrhosis (%) 6.6 8.3 n.s.
Acute hepatic failure (%) 0.6 7.3 0.01
Retransplantation (%) 6.6 12 n.s.
Other (%) 19.8 11
Surgical technique
Standard OLT 5.3 2.9 n.s.
OLT with venovenous bypass 19.7 26.9 n.s.
Piggyback technique 75 70.2 n.s.
and 1-year graft survival were similar in groups L and H
(93.4% versus 94.8, 𝑝 = n.s., and,88.1 versus 87.9%, 𝑝 = n.s.),
respectively. High preoperative bilirubin did not have any
impact on the risk of death or graft loss during the first year
after transplantation.
The incidence of early graft dysfunction (EGD) as defined
by Olthoff et al. did not differ significantly between the two
groups (65.7% in group L versus 60% in group H, 𝑝 = n.s.).
Increased preoperative bilirubin did not significantly alter the
risk for EGD (RR 0.912; OR 0.78 𝑝 = 0.25).
The rate of early retransplantation (within one month)
was similar in both groups (8/152 in group L versus 9/275
in group H, 𝑝 = n.s.). Primary graft nonfunction requiring
retransplantation did not differ significantly between groups
(5/152 in group L versus 4/275 in group H, 𝑝 = n.s.). High
preoperative bilirubin did not impact the incidence or the risk
for acute rejectionwithin the firstmonth after transplantation
(RR 1.166: OR 1.24 𝑝 = 0.37).
Recipients in group H had a longer stay on the intensive
care unit compared with group L (6.7 ± 3 versus 3.5 ± 2 days,
𝑝 < 0.05).
A subgroup analysis of the liver transplants from donors
with DRI > 2 indicated a similar incidence of EGD irre-
spective of the pretransplant bilirubin level in the recipient.
However, the rates of retransplantation at one month and
at one year were higher in group L. Patient survival at one
month and that one year after transplantation were similar in
the two subgroups (Table 2).
4. Discussion
The results of the study suggest that high preoperative bil-
irubin levels in liver graft recipients may decrease the early
biochemical signs of reperfusion injury. However, this im-
provement did not suffice to improve the outcome.
Ischemia-reperfusion injury with early graft dysfunction
(EGD) or the primary graft nonfunction (PNF) is a serious
concern following liver transplantation. PNF is life threaten-
ing and requires urgent retransplantation and thus utilizing
two livers for the same patient also impacts other patients on
the liver waiting list.
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Table 2: An overview of liver biochemistry (transaminase leak as surrogate marker for the reperfusion injury) as well as the early and late
transplant outcome in recipients receiving livers from high risk donors (DRI ≥ 2, n = 83).
Low bilirubin (<2.04mg/L) (𝑛 = 25) High bilirubin (>2.04mg/L) (𝑛 = 58) p value
AST day 1 (±SD) 2358 ± 3882 1194 ± 1411 0.02
AST day 2 (±SD) 1894 ± 3411 852 ± 1176 0.05
AST day 7 (±SD) 70 ± 58 70 ± 41 0.99
ALT day 1 (±SD) 1205 ± 1117 894 ± 823 0.09
ALT day 2 (±SD) 1370 ± 1411 911 ± 882 0.15
ALT day 7 (±SD) 258 ± 235 211 ± 117 0.33
EGD (n, %) 11 (44%) 24 (41%) 1
Re-Tx within 1 month (n, %) 5 (20%) 1 (1.8%) 0.01
Re-tx within 1 year (n, %) 7 (28%) 4 (7.5%) 0.01
Death within 1 month (n, %) 0 1 (1.8%) 1
Death within 1 year (n, %) 1 (4%) 4 (6.8%) 1
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Figure 1: Serum transaminases in the first week after transplanta-
tion in patients with low (group L, white bar) and high pretransplant
bilirubin (groupH, black bar); (a) aspartate aminotransferase (AST);
(b) alanine aminotransferase (ALT); ∗𝑝 < 0.05.
Experimental studies indicate that exposure to byprod-
ucts of the heme oxygenase-1 pathway such as carbon
monoxide, biliverdin, or bilirubin or the upregulation of
heme oxygenase- (HO-) 1 expression may mitigate ischemia-
reperfusion injury in various organs [16–18]. Exogenous
bilirubin has potent antioxidant and protective properties in
IRImodels even atmilimolar concentrations.This interesting
hypothesis may have a straightforward biochemical expla-
nation, since bilirubin may undergo oxidation to biliverdin
at reperfusion, when intense oxidative stress ensues [6].
Thus, increased amounts of cytoprotective biliverdin may be
rapidly generated without increasing the amount of noxious
ferrous iron.
Donor-recipient selection and matching is an important
topic when establishing optimal allocation strategies [19,
20]. Patients in group H had significantly higher MELD
score and one may have expected grafts of better quality
for these sicker patients. However, the grafts in the two
groups had comparable donor-related variables (age, DRI,
preservation solution, cold ischemia time, or BMI > 28
as a surrogate for steatosis). Thus, organ quality as the
cause behind the observed differences in the IRI markers
can be excluded. However, despite biochemical signs of a
milder reperfusion injury, patients with higher bilirubin
(and subsequently higher MELD) had a more complicated
postoperative course, reflected by the longer median ICU
stay and the early mortality.This finding is neither surprising
nor new and indicates that whatever supposed cytoprotection
bilirubin may entail it is insufficiently potent to outweigh the
challenges of early posttransplant period [21].
Experimental HO-1 upregulation has demonstrated a
marked antioxidant effect, allowing a more efficient degrada-
tion of the toxic, prooxidant heme molecule [22]. Moreover,
experimental administration of either carbon monoxide or
biliverdin to either organ donors or recipients greatly reduced
reperfusion injury as well as the occurrence of acute and
chronic rejection and it has been suggested that all these
compounds may have intrinsic cytoprotective, antiapoptotic,
and immunomodulatory effects [23–25]. It seems that even
a brief contact with bilirubin improves preservation injury,
through mechanisms mimicking HO-1 preconditioning [8].
The induction of HO-1 demonstrated immunomodula-
tory effect in various transplantationmodels and reduced the
frequency of acute rejection in different transplant models
[26–28]. Our study did not find any significant difference
between the two groups in incidence of acute rejection
during the first month implying that bilirubin and/or any
putative mechanisms did not change (either increase or
decrease) the immunogenicity of the livers in the two groups.
Alternatively, the potent immunosuppressive regimen used
throughout the study overshadowed any theoretical benefits
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of bilirubin or its byproducts and compensated for any
presumed immunomodulatory effect in recipients with low
bilirubin.
An earlier study investigated the protective role of
increased preoperative bilirubin against IRI and found no
relationship between the preoperative bilirubin and IRI
(transaminase leak) [29]. However, the study of Manzinate
et al. has several drawbacks that may have led to some
incorrect conclusions. The study pooled peak AST values at
different postoperative days during the first five days instead
of studying them at specific time points. In addition, the study
did not attempt any grouping according to bilirubin levels
nor did it analyze important confounding factors such as
donor age, BMI, and cold ischemia time. The controversy is
further fueled by a recent study conducted in living donor
liver transplantation which confirmed the protective effects
of increased bilirubin against ischemia-reperfusion injury but
did not find clinical outcome [30].
The current findings partly confirm the existing evidence
on a beneficial effect of bilirubin against IR injury, yet the
effect is mild and has an unclear clinical significance. This
cytoprotective effect remained low when livers with high
DRI were analyzed separately. Most evidence on bilirubin-
induced protection against IRI comes from experimental
studies, utilizing young, healthy animals. The experimental
setting offers the possibility of a tightly controlled timing and
dose of the preconditioning agent, whereas our study resem-
bles more a per- and postconditioning protocol. Moreover,
the livers in the clinical studies endure the immunological
storm secondary to the brain death and are submitted to an
additional injury disregarded by virtually any animal study.
A drawback of the current study is pooling the different
types of bilirubin (direct and indirect) instead of studying
them separately. This originates in the retrospective nature
of the study and the existing clinical routines that do not
differentiate between the different fractions (total bilirubin).
It is generally acknowledged that unconjugated bilirubin has
the highest lipophilic and antioxidant properties, though
all bilirubin types may have antioxidant properties [7, 31].
Although the amount of unconjugated bilirubin is dependent
onmany factors and it is low in the healthy individual (<20%),
the increase in total bilirubin during various liver diseases
regularly leads to high levels of unconjugated, indirect biliru-
bin. Thus, one study found an initial difference of 10mg/dL
between the total and conjugated bilirubin in patients with
liver failure undergoing albumin dialysis [32]. Therefore, we
can expect that high amounts of indirect bilirubin were
present in group H at the time of transplantation.
Another limitation of the study is the lack of histopathol-
ogy analysis to score graft steatosis. At our center, we do
not perform routinely preimplantation biopsies and only
in selected cases is a biopsy taken to assess the degree of
steatosis. Nonetheless, we used donor BMI as a surrogate
marker of the liver steatosis as BMI over 28 has been
suggested to be predictive ofmoderate or severe liver steatosis
[33]. Since graft biopsies are performed at the end of the
procedure after variable periods of reperfusion and IRI may
be in different stages of development we did not use graft
biopsies to score IRI. Previous reports confirmed the ability
of transaminases to reflect the degree of IRI in clinical
liver transplantation; hence, we used transaminases alone to
assess the hepatocellular injury after reperfusion [34]. We
limited our recipient analysis to the MELD score and did
not include other possible recipient risk factors for IRI (e.g.,
pressors, acidosis, and infections). However, by excluding
portocaval hemitransposition or split livers from the analysis,
we avoided potential significant source of transaminase leak
or postoperative comorbidities in our series.We interpret IRI
as the major cause of the transaminase elevation following
liver transplantation in our study.
5. Conclusions
Increased bilirubin appears to reduce the early biochemical
signs of reperfusion injury after liver transplantation. How-
ever, this improvement is insufficient to impact decisively the
early and late clinical outcome.
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